[go: up one dir, main page]

PE20030849A1 - Agonistas del receptor 2 del factor liberador de la corticotropina - Google Patents

Agonistas del receptor 2 del factor liberador de la corticotropina

Info

Publication number
PE20030849A1
PE20030849A1 PE2003000041A PE2003000041A PE20030849A1 PE 20030849 A1 PE20030849 A1 PE 20030849A1 PE 2003000041 A PE2003000041 A PE 2003000041A PE 2003000041 A PE2003000041 A PE 2003000041A PE 20030849 A1 PE20030849 A1 PE 20030849A1
Authority
PE
Peru
Prior art keywords
agonists
factor receptor
releasing factor
corticotropin releasing
peptide
Prior art date
Application number
PE2003000041A
Other languages
English (en)
Inventor
Robert Joseph Isfort
Wieslaw Adam Mazur
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of PE20030849A1 publication Critical patent/PE20030849A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE REFIERE A PEPTIDOS AISLADOS AGONISTAS DEL RECEPTOR DEL FACTOR LIBERADOR DE CORTICOTROPINA (CRF2R) Y ACIDOS NUCLEICOS QUE CODIFICAN LOS MISMOS; UN PEPTIDO NO NATIVO DE SECUENCIA -X2X3PSLSIDX10PX12X13X14LLRTLLELEKTQSQRERAEQNAX36IFAX40V, DONDE: X2 ES D; NADA; X3 ES NADA; N; X10 ES L, V; X12 ES L, F; X13 ES L, F, Y; X14 ES I, L, M; X36 ES R, H, Q; X40 ES H, R. LOS PEPTIDOS SON DE PREFERENCIA DE 41 AMINOACIDOS; TAMBIEN SE REFIERE A UN ANTICUERPO AISLADO ESPECIFICO DEL PEPTIDO; EL PEPTIDO PUEDE SER UTIL PARA EL TRATAMIENTO DE ATROFIA DEL MUSCULO ESQUELETICO O UNA FORMA DE DISTROFIA MUSCULAR
PE2003000041A 2002-01-16 2003-01-14 Agonistas del receptor 2 del factor liberador de la corticotropina PE20030849A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34911702P 2002-01-16 2002-01-16
US37633702P 2002-04-29 2002-04-29
US38889502P 2002-06-14 2002-06-14
US41198802P 2002-09-19 2002-09-19

Publications (1)

Publication Number Publication Date
PE20030849A1 true PE20030849A1 (es) 2003-12-01

Family

ID=27617822

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2003000040A PE20030974A1 (es) 2002-01-16 2003-01-14 Agonistas del receptor 2 del factor liberador de la corticotropina
PE2003000041A PE20030849A1 (es) 2002-01-16 2003-01-14 Agonistas del receptor 2 del factor liberador de la corticotropina
PE2003000039A PE20030747A1 (es) 2002-01-16 2003-01-14 Agonistas del receptor 2 del factor liberador de la corticotropina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2003000040A PE20030974A1 (es) 2002-01-16 2003-01-14 Agonistas del receptor 2 del factor liberador de la corticotropina

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2003000039A PE20030747A1 (es) 2002-01-16 2003-01-14 Agonistas del receptor 2 del factor liberador de la corticotropina

Country Status (29)

Country Link
US (7) US7192924B2 (es)
EP (4) EP1724283B1 (es)
JP (3) JP4508649B2 (es)
KR (3) KR100758857B1 (es)
CN (3) CN100475844C (es)
AR (3) AR038144A1 (es)
AT (4) ATE398632T1 (es)
AU (2) AU2003205197B2 (es)
BR (3) BR0306838A (es)
CA (3) CA2470743C (es)
CY (1) CY1106133T1 (es)
DE (4) DE60313845T2 (es)
DK (2) DK1465921T3 (es)
ES (4) ES2309909T3 (es)
IL (5) IL162529A0 (es)
MA (3) MA27592A1 (es)
MX (3) MXPA04006885A (es)
MY (1) MY140306A (es)
NO (3) NO20043371L (es)
NZ (3) NZ533600A (es)
PE (3) PE20030974A1 (es)
PL (3) PL373139A1 (es)
PT (2) PT1465921E (es)
RU (1) RU2294333C2 (es)
SA (3) SA03230565B1 (es)
SI (1) SI1465921T1 (es)
TW (3) TW200302278A (es)
WO (3) WO2003062268A2 (es)
ZA (1) ZA200404995B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2427490A1 (en) * 2000-09-22 2002-03-28 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr)
US7192924B2 (en) * 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists
WO2005103690A2 (en) * 2004-04-24 2005-11-03 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with corticotropin releasing hormone receptor 2 (crhr2)
EP1871888A4 (en) * 2005-03-30 2013-08-21 Novartis Vaccines & Diagnostic HAEMOPHILUS INFLUENZAE OF TYPE B
US7815905B2 (en) 2006-01-27 2010-10-19 Research Development Foundation Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors
WO2009033773A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use endothelin 2, alone or combined with a nonapeptide, a peptide as a therapeutic agent
EP2197467A2 (en) * 2007-09-11 2010-06-23 Mondobiotech Laboratories AG Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis
WO2009046874A1 (en) * 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Therapeutic combination of trh-potentiating peptide and stresscopin
BRPI0921640A2 (pt) * 2008-11-04 2019-09-24 Janssen Pharmaceutica Nv agonistas peptídicos do crhr2 e usos do mesmo
EP2206726A1 (en) * 2009-01-08 2010-07-14 Universite Joseph Fourier Non-invasive tools for detecting vulnerable atherosclerotic plaques
EP2496248A2 (en) * 2009-11-04 2012-09-12 Janssen Pharmaceutica, N.V. Method for treating heart failure with stresscopin-like peptides
US9314506B2 (en) 2011-10-24 2016-04-19 Research Development Foundation Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors
DK2814513T3 (en) 2012-02-14 2018-02-26 Univ California Systemic administration and regulated expression of paracrine for cardiovascular disease and other conditions
JOP20170153A1 (ar) * 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
KR20190084055A (ko) * 2016-10-20 2019-07-15 코르텐 인코포레이티드 부적응 스트레스 반응에서 기인한 질환의 치료 방법
CN110755434B (zh) * 2018-07-27 2022-03-15 中国医学科学院药物研究所 化合物palosuran防治骨骼肌萎缩等疾病的用途
WO2025184558A1 (en) * 2024-02-28 2025-09-04 Caradon Therapeutics, Inc. Modified urocortin 3
TW202544027A (zh) * 2024-04-19 2025-11-16 美商紐羅克里生物科學有限公司 促皮質素釋放因子受體２（ｃｒｆｒ２）促效劑
AU2025204485B2 (en) * 2024-04-30 2025-12-11 Hanmi Pharm. Co. Ltd. Use of crf2 receptor agonist and the acylated conjugates thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5235036A (en) 1991-05-31 1993-08-10 The Salk Institute For Biological Studies Crf analogs
EP0860501A3 (en) 1994-06-14 1999-05-19 Neurocrine Biosciences, Inc. Corticotropin-releasing factor2 receptors
US5786203A (en) * 1994-06-14 1998-07-28 Neurocrine Biosciences, Inc. Isolated nucleic acid encoding corticotropin-releasing factor2 receptors
US5824771A (en) 1994-12-12 1998-10-20 The Salk Institute For Biological Studies Cyclic CRF agonists
US5663292A (en) 1994-12-12 1997-09-02 The Salk Institute For Biological Studies Cyclic CRF analogs
US5660824A (en) 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
EP0845035A2 (en) 1995-06-13 1998-06-03 The Salk Institute For Biological Studies Urocortin peptides
US5869450A (en) 1996-03-06 1999-02-09 The Regents Of The University Of California Anti-inflammatory compositions and method with corticotropin-releasing factor analogs
KR100879232B1 (ko) 2000-08-04 2009-01-20 리서치 디벨럽먼트 파운데이션 우로코르틴 단백질 및 이를 포함하는 약제학적 조성물
CA2427490A1 (en) * 2000-09-22 2002-03-28 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Methods for improving the antagonistic/agonistic properties of peptidic antagonists/agonists of the corticotropin-releasing factor receptor (crfr)
US20020082409A1 (en) 2000-10-26 2002-06-27 Hsu Sheau Yu Stresscopins and their uses
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
US7192924B2 (en) 2002-01-16 2007-03-20 The Procter & Gamble Company Corticotropin releasing factor 2 receptor agonists

Also Published As

Publication number Publication date
US20060025339A1 (en) 2006-02-02
PL373139A1 (en) 2005-08-22
US20080004435A1 (en) 2008-01-03
WO2003062268A2 (en) 2003-07-31
CA2470656C (en) 2011-06-28
DK1465923T3 (da) 2007-07-02
BR0306826A (pt) 2005-09-06
BR0306838A (pt) 2005-04-05
CA2470731A1 (en) 2003-07-31
AU2003205197B2 (en) 2006-03-02
JP4489434B2 (ja) 2010-06-23
KR100758857B1 (ko) 2007-09-14
AU2003237419B2 (en) 2006-04-13
DE60313845T2 (de) 2008-01-31
EP1724283A3 (en) 2007-04-11
CN1617885A (zh) 2005-05-18
DK1465921T3 (da) 2006-11-27
CA2470743C (en) 2011-12-13
EP1465923B1 (en) 2007-05-16
NZ533599A (en) 2007-03-30
ZA200404995B (en) 2005-06-29
SA03230564A (ar) 2005-12-03
IL162530A0 (en) 2005-11-20
PT1465921E (pt) 2006-12-29
MA27590A1 (fr) 2005-11-01
TW200302277A (en) 2003-08-01
US7462597B2 (en) 2008-12-09
MY140306A (en) 2009-12-31
CA2470743A1 (en) 2003-07-31
NO20043396L (no) 2004-10-06
CN1617887A (zh) 2005-05-18
NZ533600A (en) 2007-02-23
ATE398632T1 (de) 2008-07-15
US20030148958A1 (en) 2003-08-07
US20090124793A1 (en) 2009-05-14
PE20030974A1 (es) 2003-12-26
SA03230564B1 (ar) 2006-10-31
TWI300442B (en) 2008-09-01
WO2003062277A1 (en) 2003-07-31
MXPA04006884A (es) 2004-12-06
CN100391972C (zh) 2008-06-04
JP2005522191A (ja) 2005-07-28
SA03230565A (ar) 2005-12-03
PL373529A1 (en) 2005-09-05
IL196384A0 (en) 2011-07-31
BR0306878A (pt) 2004-10-26
CN1617886A (zh) 2005-05-18
ES2269976T3 (es) 2007-04-01
ATE362488T1 (de) 2007-06-15
SI1465921T1 (sl) 2006-10-31
NO20043366L (no) 2004-10-06
PL371364A1 (en) 2005-06-13
MXPA04006885A (es) 2004-12-06
TW200302276A (en) 2003-08-01
US7608701B2 (en) 2009-10-27
RU2004124847A (ru) 2005-04-20
MA27591A1 (fr) 2005-11-01
DE60313845D1 (de) 2007-06-28
WO2003062268A3 (en) 2003-11-27
TW200302278A (en) 2003-08-01
CA2470656A1 (en) 2003-07-31
US6936585B2 (en) 2005-08-30
ES2299701T3 (es) 2008-06-01
KR20040082390A (ko) 2004-09-24
ES2287484T3 (es) 2007-12-16
AR038144A1 (es) 2004-12-29
PT1465923E (pt) 2007-08-06
DE60318547T2 (de) 2008-12-24
JP4508648B2 (ja) 2010-07-21
MA27592A1 (fr) 2005-11-01
HK1078095A1 (zh) 2006-03-03
WO2003062269A2 (en) 2003-07-31
WO2003062269A3 (en) 2003-11-06
IL197774A0 (en) 2009-12-24
US20030148956A1 (en) 2003-08-07
EP1465921A2 (en) 2004-10-13
SA03230565B1 (ar) 2006-10-31
DE60307044T2 (de) 2007-02-15
ES2309909T3 (es) 2008-12-16
IL162529A0 (en) 2005-11-20
US7192923B2 (en) 2007-03-20
US7192924B2 (en) 2007-03-20
ATE334147T1 (de) 2006-08-15
EP1724283B1 (en) 2008-06-18
KR20040082389A (ko) 2004-09-24
EP1465921B1 (en) 2006-07-26
KR100758858B1 (ko) 2007-09-14
ATE383372T1 (de) 2008-01-15
KR20040082392A (ko) 2004-09-24
US20100197579A1 (en) 2010-08-05
US7897731B2 (en) 2011-03-01
MXPA04006883A (es) 2004-12-06
DE60321730D1 (de) 2008-07-31
DE60307044D1 (de) 2006-09-07
CA2470731C (en) 2011-06-21
AR038142A1 (es) 2004-12-29
AR038143A1 (es) 2004-12-29
US20030148957A1 (en) 2003-08-07
CY1106133T1 (el) 2011-06-08
JP2005521387A (ja) 2005-07-21
EP1465922B1 (en) 2008-01-09
EP1465923A1 (en) 2004-10-13
PE20030747A1 (es) 2003-10-23
IL162431A0 (en) 2005-11-20
EP1465922A2 (en) 2004-10-13
JP2005525101A (ja) 2005-08-25
RU2294333C2 (ru) 2007-02-27
DE60318547D1 (de) 2008-02-21
NO20043371L (no) 2004-10-06
NZ533598A (en) 2007-03-30
EP1724283A2 (en) 2006-11-22
KR100735586B1 (ko) 2007-07-04
US7632933B2 (en) 2009-12-15
JP4508649B2 (ja) 2010-07-21
CN100475844C (zh) 2009-04-08

Similar Documents

Publication Publication Date Title
PE20030849A1 (es) Agonistas del receptor 2 del factor liberador de la corticotropina
ES2558330T3 (es) Péptido WT1 restringido por HLA-A*3303 y composición farmacéutica que comprende el mismo
ES2526292T3 (es) Antagonistas de la somatostatina selectivos para receptor (SSTR2)
MX2010004298A (es) Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1.
EA200870237A1 (ru) Последовательности пептидов и композиции
AR093903A1 (es) Coagonistas de glucagon y glp-1 para el tratamiento de la obesidad
NZ628987A (en) Extended recombinant polypeptides and compositions comprising same
AR076349A1 (es) Peptido auxiliar del antigeno del cancer
AR072159A1 (es) Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad
CR9452A (es) Agentes terapeuticos a base de peptidos de toxinas
BRPI0411321A (pt) vetor viral associado a adenovìrus, composição farmacêutica e método para tratar doença de alzheimer, e, uso do vetor viral associado a adenovìrus
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
CY1105616T1 (el) ΠΕΠΤΙΔΙΑ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TGFβ1
MX2021015160A (es) Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso.
PE20070684A1 (es) MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
CL2019003410A1 (es) Péptido asociado a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprende el péptido; método para producir el péptido; uso para preparar un medicamento útil para tratar el cáncer; kit farmacéutico. (divisional solicitud 201702407).
AR067980A1 (es) Peptidos de cdh3 y agentes que los comprenden
AR008765A1 (es) Un peptido o un derivado, analogo o variante, funcional del mismo, un peptido recombinante o sintetico del mismo, una secuencia nucleotidica y vectorque la contiene, una celula huesped transformada, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un compuesto del
UY24651A1 (es) Método para la síntesis de analogos de la hormona paratiroidea y del peptido relacionado con la hormona paratiroidea.
AR042039A1 (es) Isomeros posicionales del ifn peg alfa 2 a
CY1114121T1 (el) Λυοφιλοποιημενα σκευασματα fsh/lh
PE20050962A1 (es) Anticuerpos completamente humanos contra 4-1bb humano
DE60312136D1 (de) Radiofluorierungsverfahren
EA200400427A1 (ru) Применение человеческого хорионического гонадотропина и лютеинизирующего гормона при контролируемой гиперстимуляции яичников
DE602004028266D1 (de) Angiogene peptide und ihre verwendungen

Legal Events

Date Code Title Description
FC Refusal